March 3 (Reuters) - Helix Biopharma Corp HBP.TO :
* Reports on advancement of its lung cancer drug candidate L-DOS47
* Says there have been no dose limiting toxicities reported to-date and L-DOS47
continues to be well tolerated by patients
* Source text for Eikon
* Further company coverage HBP.TO